Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Pipeline Review, H1 2016

Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Pipeline Review, H1 2016
Published Jun 30, 2016
42 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Pipeline Review, H1 2016, provides in depth analysis on Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted pipeline therapeutics.

The report provides comprehensive information on the Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46)
- The report reviews Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics and enlists all their major and minor projects
- The report assesses Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehy

  
Source:
Document ID
GMDHC0329TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Overview61
Therapeutics Development73
  Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Products under Development by Stage of Development71
  Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Products under Development by Therapy Area81
  Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Products under Development by Indication91
Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Pipeline Products Glance102
  Late Stage Products101
  Early Stage Products111
Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Products under Development by Companies122
Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Therapeutics Assessment145
  Assessment by Monotherapy/Combination Products141
  Assessment by Mechanism of Action151
  Assessment by Route of Administration162
  Assessment by Molecule Type181
Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Companies Involved in Therapeutics Development192
  Nivalis Therapeutics, Inc.191
  Saje Pharma, LLC201
Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Drug Profiles219
  N-91115 Drug Profile213
  N-91138 Drug Profile241
  N-91169 Drug Profile251
  SPL-227.1 Drug Profile261
  SPL-334.1 Drug Profile271
  SPL-875.1 Drug Profile281
  SPL-891.1 Drug Profile291
Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Dormant Projects302
Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Discontinued Products321
Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Featured News &Press Releases338
  May 16, 2016: Nivalis Therapeutics Announces First Patient Dosed in Second Phase 2 Study of N91115 for Treatment of Cystic Fibrosis331
  Apr 05, 2016: Nivalis Therapeutics Reaches 50 Percent Enrollment Milestone in Phase 2 Clinical Trial in Cystic Fibrosis331
  Mar 07, 2016: Nivalis Therapeutics Expands N91115 Clinical Development Program in Cystic Fibrosis341
  Mar 01, 2016: Nivalis Therapeutics Announces Appointment of Paul Sekhri to Its Board of Directors351
  Feb 29, 2016: Nivalis Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results351
  Feb 18, 2016: Nivalis Therapeutics Announces FDA Fast Track Designation for N91115 in Patients With Cystic Fibrosis361
  Jan 15, 2016: Nivalis Therapeutics Announces FDA Orphan Drug Designation for N91115 in Cystic Fibrosis371
  Dec 01, 2015: Nivalis Therapeutics Announces First Patient Dosed in Phase 2 Study of N91115 for Treatment of Cystic Fibrosis371
  Oct 07, 2015: Nivalis Therapeutics Announces Positive Phase 1b Results for N91115 in Patients With Cystic Fibrosis and Plans to Initiate Phase 2 Trial381
  Mar 14, 2014: N30 Pharmaceuticals Initiates Phase 1 Clinical Trial for Novel Cystic Fibrosis Therapy391
  Mar 12, 2014: N30 Announces Start of Oral Dosing of N91115 in a Phase 1 Clinical Trial392
Appendix412
  Methodology411
  Coverage411
  Secondary Research411
  Primary Research411
  Expert Panel Validation411
  Contact Us411
  Disclaimer421

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Formaldehyde-Dehydrogenase-S-Nitrosoglutathione-Reductase-or-NAD-Dependent-Formaldehyde-Dehydrogenase-or-EC-1-2-1-46-Pipeline-Review-H1-2016-2088-16148>
  
APA:
Global Markets Direct - Market Research. (2016). Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Formaldehyde-Dehydrogenase-S-Nitrosoglutathione-Reductase-or-NAD-Dependent-Formaldehyde-Dehydrogenase-or-EC-1-2-1-46-Pipeline-Review-H1-2016-2088-16148>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.